Cytomegalovirus-associated allograft rejection in heart transplant patients

Current Opinion in Infectious Diseases

Volumn 20, Issue 4, 2007, Pages 425-431

  Potena, Luciano ^a   Valantine, Hannah A ^b,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary allograft vasculopathy; Cytomegalovirus; Heart transplantation

Indexed keywords

GANCICLOVIR; HYPERIMMUNE GLOBULIN;

CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION PREVENTION; PATHOGENESIS; PREVENTION AND CONTROL; REVIEW; VASCULAR DISEASE; VIRUS REPLICATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; POSTOPERATIVE COMPLICATIONS;

EID: 34347386490     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328259c33b     Document Type: Review

References (73)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report - 2006. J Heart Lung Transplant 2006; 25:869-879.
2. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant 'atheroma'. Transplantation 2003; 76:891-899.
3. Mehra M. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006; 6:1248-1256. This paper is a clear review of the state-of-the-art therapeutic strategies devoted to CAV prevention and treatment.
4. Mocarski E. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 2004; 6:707-717.
5. Abate D, Watanabe S, Mocarski E. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol 2004; 78:10995-11006.
6. Vamvakopoulos J, Hayry P. Cytomegalovirus and transplant arteriopathy: evidence for a link is mounting, but the jury is still out. Transplantation 2003; 75:742-743.
7. Grattan M, Moreno-Cabral C, Starnes V, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-3566.
8. Loebe M, Schuler S, Zais O, et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Lung Transplant 1990; 9:707-711.
9. Mc Donald K, Rector S, Braunlin E, et al. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989; 64:359-362.
10. Koskinen P, Lemstrom K, Bruggeman C, et al. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. Am J Pathol 1994; 144:41-50.
11. Merigan T, Renlund D, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326:1182-1186.
12. Lemstrom K, Sihvola R, Bruggeman C, et al. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 1997; 95:2614-2616.
13. Valantine H, Gao S, Menon S, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-66.
14. Gerna G, Percivalle E, Baldanti F, et al. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients. New Microbiol 1998; 21:293-308.
15. Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004; 42:1142-1148.
16. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036.
17. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66:329-337.
18. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2:850-856.
19. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5:218-227.
20. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003; 75:839-843.
21. Potena L, Holweg CT, Vana ML, et al. Frequent occult infection with cytomegalovirus despite antiviral prophylaxis in cardiac transplant recipients. J Clin Microbiol 2007; 4 April [Epub ahead of print].
22. Potena L, Holweg C, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82:398-405. In this observational prospective paper, suppression of subclinical CMV infection by an aggressive prophylaxis strategy is shown to be clinically relevant for prevention of acute and chronic graft rejection.
23. Piiparinen H, Hockerstedt K, Gronhagen-Riska C, Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30:258-263.
24. Luckraz H, Charman SC, Wreghitt T, et al. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J Heart Lung Transplant 2003; 22:1023-1027.
25. •], this paper provides another important piece of evidence of the impact of subclinical CMV infection on graft function. Note that in both papers the highest benefit was obtained by combining CMVIG with antiviral drugs.
26. Koskinen P, Krogerus L, Nieminen M, et al. Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. J Heart Lung Transplant 1993; 12:343-354.
27. Kowalik T, Wing B, Haskill J, et al. Multiple mechanisms are implicated in the regulation of NF-kB activity during human cytomegalovirus infection. Proc Natl Acad Sci U S A 1992; 90:1107-1111.
28. Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol 1995; 69:5391-5400.
29. Laegreid A, Medvedev A, Nonstad U, et al. Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem 1994; 269:7785-7791.
30. Carlquist JF, Edelman L, Bennion DW, Anderson JL. Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB. J Infect Dis 1999; 179:1094-1100.
31. Knight DA, Waldman WJ, Sedmak DD. Cytomegalovirus-mediated modulation of adhesion molecule expression by human arterial and microvascular endothelial cells. Transplantation 1999; 68:1814-1818.
32. van Dorp WT, Jonges E, Bruggeman CA, et al. Direct induction of MHC class I, but not class II, expression on endothelial cells by cytomegalovirus infection. Transplantation 1989; 48:469-472.
33. Almeida GD, Porada CD, St Jeor S, Ascensao JL. Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood 1994; 83:370-376.
34. Smith PD, Saini SS, Raffeld M, et al. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest 1992; 90:1642-1648.
35. Okada M, Wang CY, Hwang DW, et al. Transcriptional control of cardiac allograft vasculopathy by early growth response gene-1 (Egr-1). Circ Res 2002; 91:135-142.
36. Wu YW, Lee CM, Lee YT, et al. Value of circulating adhesion molecules in assessing cardiac allograft vasculopathy. J Heart Lung Transplant 2003; 22:1284-1287.
37. Lattmann T, Hein M, Horber S, et al. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling. Am J Transplant 2005; 5:1042-1049.
38. Chee MS, Satchwell SC, Preddie E, et al. Human cytomegalovirus encodes three G protein-coupled receptor homologues. Nature 1990; 344:774-777.
39. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358:160-162.
40. Russell ME, Hancock WW, Wallace AF, et al. Modulation of inflammatory activation pathways in the Lewis-to-F-344 rat chronic cardiac rejection model. Transplant Proc 1995; 27:2100-2104.
41. Melnychuk RM, Streblow DN, Smith PP, et al. Human cytomegalovirus-encoded G protein-coupled receptor US28 mediates smooth muscle cell migration through Galpha12. J Virol 2004; 78:8382-8391.
42. Streblow DN, Kreklywich CN, Smith P, et al. Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant 2005; 5:436-442.
43. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol 2003; 23:567-575.
44. Tona F, Caforio A, Montisci R, et al. Coronary flow reserve by contrast-enhanced echocardiography: a new noninvasive diagnostic tool for cardiac allograft vasculopathy. Am J Transplant 2006; 6:998-1003. Presents a novel and potentially relevant noninvasive method to detect CAV.
45. Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104:3091-3096.
46. Weis M, Kledal TN, Lin KY, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004; 109:500-505.
47. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4:41-51.
48. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99:3092-3095.
49. Petrakopoulou P, Kubrich M, Pehlivanli S, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110:II207-II212.
50. Orloff SL, Streblow DN, Soderberg-Naucler C, et al. Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants. Transplantation 2002; 73:679-688.
51. Gulizia J, Kandolf R, Kendall T, et al. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995; 147:461-475.
52. Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol 2006; 35:349-353. This interesting review provides a new method of analyzing CMV-mediated allograft damage. The authors present and discuss recent findings pointing to the ability of single components of the viral particle to elicit an adverse reaction in the host, independent from the active viral replication.
53. Boehme KW, Singh J, Perry ST, Compton T. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol 2004; 78:1202-1211.
54. Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and toll-like receptor 2. J Virol 2003; 77:4588-4596.
55. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006; 177:7094-7102. This experimental paper provides a detailed characterization of viral proteins required for activation of native immunity pathways.
56. Goldstein DR. Toll like receptors and acute allograft rejection. Transpl Immunol 2006; 17:11-15.
57. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006; 114:1608-1615. In this paper, our group shows that specific cellular immunity directed against CMV is capable of preventing development of acute rejection and CAV.
58. Westall G, Kotsimbos T, Brooks A. CMV-specific CD8 T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation. Am J Transplant 2006; 6:577-584. Supports the concept of a potential benefit for immunotherapy to prevent CMV disease and CMV-related graft injury.
59. •], this paper focuses on the ability of specific anti-CMV T-cell immunity to prevent CMV infection after transplant. Supports the concept of a potential benefit for immunotherapy to prevent CMV disease and CMV-related graft injury.
60. Cytomegalovirus. Am J Transplant 2004; 4:51-58.
61. Dummer S. Controlling the troll: management of cytomegalovirus infection after transplantation. Ann Intern Med 2005; 143:913-914.
62. Meylan PR, Pascual M. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know. Clin Infect Dis 2006; 43:881-883. Focalized editorial underscoring the unmet questions of the studies investigating anti-CMV therapies in solid organ transplantation.
63. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105-2115.
64. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81:139-145. This metaanalysis, which includes studies on the preemptive approach, confirms its efficacy in preventing CMV disease, but is unable to demonstrate any graft-related benefit of this strategy as was demonstrated by Ref. [63].
65. Small LN, Lau J, Snydman DR. Preventing postorgan transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43:869-880. This important study partially makes up for the lack of direct comparisons between prophylaxis and the preemptive approach for prevention of CMV disease. While showing that the two strategies appear equally effective for prevention of CMV disease, prophylaxis appears to have an additional benefit related to patient survival.
66. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-880.
67. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35:866-872.
68. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81:1645-1652.
69. Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77:425-429.
70. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-1618.
71. Valantine H, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation. Transplantation 2001; 72:1647-1652.
72. Toyoda M, Petrosyan A, Pao A, Jordan SC. Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 2004; 78:1134-1138.
73. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631-636.